Nektar Posts $55.7M Q3 Loss, EPS of -$1.63 as Product Sales Reach $9.4M
NKTR is trading near its 52-week low of $33.4 (12% above the low).
Summary
Nektar reported a Q3 net loss of $55.7 million and EPS of -$1.63, with product sales of $9.4 million. The loss is wider than the $40.6 million net loss recorded in Q2, so cash burn is accelerating even as the company sits on a large cash balance. Product sales of roughly $9.4 million remain small relative to the loss, meaning the P&L is still driven by R&D spend on rezpegaldesleukin rather than commercial revenue. This lands after a volatile stretch: shares fell 19% on October 1 despite positive one-year alopecia areata data, and the company won a $90 million jury verdict against Eli Lilly in September. The $150 million at-the-market program from May remains the likely funding lever if burn stays at this level.
At the time of this announcement, NKTR was trading at $37.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $33.40 to $109.00. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.